CURRENT REPORT 19/2021
June 11, 2021

Publication of clinical data for phase I RVU120 and phase I/II SEL24 (MEN1703)

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("Company") hereby informs, in connection with a current report no 12/2021 published on May 12, 2021, about publication of clinical data for phase I RVU120 and phase I/II SEL24 (MEN1703) programs at the Annual European Hematology Association (EHA) 2021 Virtual Congress.

Key takeaways with regard to the development of both programs:

- RVU120 (CDK8/19 inhibitor): During the trial an acceptable safety profile and two clinically relevant responses were observed in the Ph I dose escalation study in the first five AML and high risk MDS patients treated: one complete response (CR) and one erythroid response,
- SEL24/MEN1703 (Dual PIM/FLT3 inhibitor): Three out of five AML patients harboring IDH mutations treated at 75-125 mg achieved CR/Cri (Complete response with incomplete hematological recovery).

The Management Board of the Company deems the data of both programs as positive given the early signs of clinical efficacy for RVU120 in both AML and high risk MDS patients who were previously treated with multiple lines of therapy as well as the results for SEL24 (MEN1703), which provide a strong rationale for further clinical development.

RVU120: orally available CDK8/19 inhibitor

The data presented at EHA 2021 covers the first four dose cohorts, in which RVU120 demonstrated favorable safety and PK profile. No DLTs were observed, and all of the reported SAEs were assessed as unlikely or not related to study drug.

Results are reported on the first five patients to receive treatment with RVU120, and the clinically relevant responses were observed in patients in the two highest dose cohorts reported:

- The Cohort 3 (50mg dose, subsequently escalated to 75 mg) patient, with HRMDS, demonstrated an erythroid response from Cycle 5 to Cycle 8 and continues on RVU120 treatment in Cycle 13 with stable disease. An erythroid response reflects a reduction in red blood cell transfusions vs. baseline.
- The Cohort 4 (75mg dose) patient, with relapsed/refractory AML, showed a response from C2 with persistence of skin leukemia, which completely resolved at C7 resulting in a CR. This patient was previously refractory to venetoclax + HMA, which is a patient population associated with poor prognosis.

Translational data will be presented as part of an Oral Session and provide a potential linkage between in vitro data showing erythroid differentiation and erythroid response in the clinic. In vitro data demonstrate that RVU120 can induce erythroid cells to differentiate and therefore rescue anemia in preclinical models.

Presented results indicate strong erythroid differentiation potential of RVU120 (SEL120) in (Lin-) CD34+, that acquired genetic abnormalities resulting in arrested erythroid commitment, a characteristic of many MDS and AML subtypes. Detailed transcriptomic profiling strongly associated differentiation with enrichment of genes representing regulators of erythroid commitment and hemoglobin metabolism. Further studies are warranted to investigate efficacy of RVU120 (SEL120) in anemias associated with bone marrow failures in AML and MDS patients.

Oral Presentation: "RVU120/SEL120 CDK8/19 inhibitor - a drug candidate for the treatment of MDS can induce erythroid differentiation in transformed CD34+ hematopoietic progenitor cells" (S164)

- Presentation ID: p412-5
- Date and Time: on-demand video recording is now available, followed by a Live Q&A Session on Wednesday, June 16 (13:00 - 13:45 CEST)

Poster Presentation: "CLI120-001 Phase1b Study of SEL120/RVU120 in patients with AML or High Risk MDS: Preliminary clinical and PK results from initial dose escalation cohorts" (EP480)

- Poster ID: EP480

SEL24/MEN1703: orally available dual PIM/FLT3 inhibitor

A clinical poster on the first-in-human study of SEL24/MEN1703, the DIAMOND-01 trial conducted by Ryvu's partner Menarini Group, reports four objective responses across the dose escalation (n=25) and cohort expansion (n=23) in patients with AML, with 3 of those 4 responders harboring an IDH mutation. Notably, three out of five patients with IDH

mutations treated at doses of 75-125 mg achieved a CR/CRi, including a patient that relapsed on the IDH-inhibitor enasidenib. Furthermore, one patient with an IDH1 mutation achieved a CRi and underwent allogeneic-HSCT.

At the recommended dose (n=30) of 125mg/day as selected in the dose escalation phase, SEL24/MEN1703 showed a manageable safety profile. Most Grade 3 or higher treatment-emergent adverse events (TEAEs) were hematologic or infectious in nature.

Poster Presentation: "Results from DIAMOND-01 (CLI24-001) TRIAL: First in Human Study of SEL24/MEN1703, a Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia" (EP455)

- Poster ID: EP455

All presentations and posters are now available online and can be obtained from conference site: https://eha2021.ehaweb.org/.

On June 11, at 1:00 PM CEST (7:00 AM ET), Ryvu Therapeutics will hold a conference call to discuss the data presented at EHA 2021. Access to the call will be available at: live.ryvu.com.

Legal basis: Article 17(1) of the Market Abuse Regulation (MAR) – confidential information.

Representatives of the Company:

- Paweł Przewięźlikowski – President of the Management Board
- Kamil Sitarz – Member of the Management Board